Btw, Imho (fwiw) the real unfortunate ones are those suffering the barrage of inappropriate analyses from posters who openly admit they don't have a clue in applying valuation models to early stage biotechs.
@Naughty Morty,
Instead of lamenting about those with the inability to value early stage biotechs, for the benefit of those "unfortunate ones suffering inappropriate analyses", why don't you simply offer the alternative, namely your own valuation and - more importantly - how you derived it?
How about it: what is your valuation of MSB, and why (assuming it is not merely a re-cycling of a Target Price from some or other stockbroking report)?
Btw, Imho (fwiw) the real unfortunate ones are those suffering...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.050(4.39%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.17 | $1.07 | $8.385M | 7.489M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8500 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 26954 | 3 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |